ArticleBiomarkers in medicine2025
mSEPT9 performs better than CEA in NAT response and MRD assessment and recurrence prediction of stage III CRC.
Article in Biomarkers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Navigating the molecular landscape: integrated multiomics liquid biopsy for biomarker discovery in early detection and monitoring of colorectal cancer.Frontiers in molecular biosciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsThis study aimed to investigate the capability of methylated SEPT9 (mSEPT9) assay in assessing the neoadjuvant therapy (NAT) response,the minimal residual disease (MRD) and predicting the recurrence of stage III colorectal cancer (CRC). MATERIALS &
methodsWe prospectively recruited 124 stage III CRC patients. All patients received pre-surgical NAT and subsequent curative surgery, and were followed up to 627 days. Blood samples were collected before NAT, after NAT and after surgery. Measurements of mSEPT9 and CEA were performed.
resultsmSEPT9 exhibited a positive detection rate (PDR) of 82.6% for stage III CRC, significantly higher than that of the carcinoembryonic antigen (CEA) (60.3%,
conclusionmSEPT9 exhibits better applicability than CEA in assessment in terms of patient coverage, sensitivity and the pre-NAT recurrence prediction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.